Fulcrum Therapeutics Net Income
| FULC Stock | USD 10.49 0.15 1.45% |
As of the 11th of February 2026, Fulcrum Therapeutics shows the Coefficient Of Variation of 1147.7, downside deviation of 4.34, and Mean Deviation of 4.27. Fulcrum Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Fulcrum Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 117.3999 | Earnings Share (1.14) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -8.8 M | -9.2 M | |
| Net Loss | -98.9 M | -103.8 M | |
| Net Loss | -8.8 M | -9.2 M | |
| Net Loss | (0.14) | (0.15) |
Fulcrum | Net Income | Build AI portfolio with Fulcrum Stock |
Analyzing Fulcrum Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Fulcrum Therapeutics's current valuation and future prospects.
Latest Fulcrum Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Fulcrum Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Fulcrum Therapeutics financial statement analysis. It represents the amount of money remaining after all of Fulcrum Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Fulcrum Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fulcrum Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.72 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Fulcrum Net Income Regression Statistics
| Arithmetic Mean | (39,826,978) | |
| Coefficient Of Variation | (82.31) | |
| Mean Deviation | 27,524,248 | |
| Median | (22,964,000) | |
| Standard Deviation | 32,783,116 | |
| Sample Variance | 1074.7T | |
| Range | 101.1M | |
| R-Value | (0.28) | |
| Mean Square Error | 1056T | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | (1,822,506) | |
| Total Sum of Squares | 17195.7T |
Fulcrum Net Income History
Other Fundumenentals of Fulcrum Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Fulcrum Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Fulcrum Therapeutics is extremely important. It helps to project a fair market value of Fulcrum Stock properly, considering its historical fundamentals such as Net Income. Since Fulcrum Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Fulcrum Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Fulcrum Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Fulcrum diversify its offerings? Factors like these will boost the valuation of Fulcrum Therapeutics. Market participants price Fulcrum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fulcrum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fulcrum Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Fulcrum Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Fulcrum Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Fulcrum Therapeutics.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Fulcrum Therapeutics on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Fulcrum Therapeutics or generate 0.0% return on investment in Fulcrum Therapeutics over 90 days. Fulcrum Therapeutics is related to or competes with Cencora, Regeneron Pharmaceuticals, IDEXX Laboratories, Haleon Plc, Cigna Corp, Elevance Health, and Becton Dickinson. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the... More
Fulcrum Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Fulcrum Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Fulcrum Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.34 | |||
| Information Ratio | 0.0747 | |||
| Maximum Drawdown | 53.8 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 11.56 |
Fulcrum Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fulcrum Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Fulcrum Therapeutics' standard deviation. In reality, there are many statistical measures that can use Fulcrum Therapeutics historical prices to predict the future Fulcrum Therapeutics' volatility.| Risk Adjusted Performance | 0.0787 | |||
| Jensen Alpha | 0.7481 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.1287 | |||
| Treynor Ratio | (0.50) |
Fulcrum Therapeutics February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0787 | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 4.27 | |||
| Semi Deviation | 4.02 | |||
| Downside Deviation | 4.34 | |||
| Coefficient Of Variation | 1147.7 | |||
| Standard Deviation | 7.48 | |||
| Variance | 55.92 | |||
| Information Ratio | 0.0747 | |||
| Jensen Alpha | 0.7481 | |||
| Total Risk Alpha | (0.13) | |||
| Sortino Ratio | 0.1287 | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 53.8 | |||
| Value At Risk | (7.75) | |||
| Potential Upside | 11.56 | |||
| Downside Variance | 18.86 | |||
| Semi Variance | 16.16 | |||
| Expected Short fall | (5.17) | |||
| Skewness | 3.68 | |||
| Kurtosis | 20.56 |
Fulcrum Therapeutics Backtested Returns
Fulcrum Therapeutics appears to be slightly risky, given 3 months investment horizon. Fulcrum Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0677, which denotes the company had a 0.0677 % return per unit of risk over the last 3 months. By reviewing Fulcrum Therapeutics' technical indicators, you can evaluate if the expected return of 0.53% is justified by implied risk. Please utilize Fulcrum Therapeutics' Coefficient Of Variation of 1147.7, downside deviation of 4.34, and Mean Deviation of 4.27 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Fulcrum Therapeutics holds a performance score of 5. The firm shows a Beta (market volatility) of -1.29, which means a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Fulcrum Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Fulcrum Therapeutics is expected to outperform it. Please check Fulcrum Therapeutics' jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to make a quick decision on whether Fulcrum Therapeutics' price patterns will revert.
Auto-correlation | -0.18 |
Insignificant reverse predictability
Fulcrum Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Fulcrum Therapeutics time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Fulcrum Therapeutics price movement. The serial correlation of -0.18 indicates that over 18.0% of current Fulcrum Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.18 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.3 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Fulcrum Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Fulcrum Therapeutics reported net income of (9.72 Million). This is 102.85% lower than that of the Pharmaceuticals sector and 113.88% lower than that of the Health Care industry. The net income for all United States stocks is 101.7% higher than that of the company.
Fulcrum Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fulcrum Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fulcrum Therapeutics could also be used in its relative valuation, which is a method of valuing Fulcrum Therapeutics by comparing valuation metrics of similar companies.Fulcrum Therapeutics is currently under evaluation in net income category among its peers.
Fulcrum Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Fulcrum Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Fulcrum Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Fulcrum Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Fulcrum Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Fulcrum Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Fulcrum Therapeutics' value.| Shares | D. E. Shaw & Co Lp | 2025-06-30 | 1.2 M | Goldman Sachs Group Inc | 2025-06-30 | 1.1 M | Woodline Partners Lp | 2025-06-30 | 897.6 K | Northern Trust Corp | 2025-06-30 | 611.5 K | Point72 Asset Management, L.p. | 2025-06-30 | 498.2 K | Amvescap Plc. | 2025-06-30 | 470.3 K | Exome Asset Management Llc | 2025-06-30 | 444.9 K | Ikarian Capital, Llc | 2025-06-30 | 428.5 K | Charles Schwab Investment Management Inc | 2025-06-30 | 387.8 K | Ra Capital Management, Llc | 2025-06-30 | 10.2 M | Tcg Crossover Management, Llc | 2025-06-30 | 5.2 M |
Fulcrum Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 449.58 M | ||||
| Shares Outstanding | 65.97 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 80.48 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (1.99) X | ||||
| Price To Book | 3.24 X | ||||
| Price To Sales | 5.12 X | ||||
| Revenue | 80 M | ||||
| Gross Profit | (52.4 M) | ||||
| EBITDA | (18.24 M) | ||||
| Net Income | (9.72 M) | ||||
| Cash And Equivalents | 221.79 M | ||||
| Cash Per Share | 4.26 X | ||||
| Total Debt | 8.63 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 15.49 X | ||||
| Book Value Per Share | 3.67 X | ||||
| Cash Flow From Operations | (2.22 M) | ||||
| Short Ratio | 4.02 X | ||||
| Earnings Per Share | (1.14) X | ||||
| Price To Earnings To Growth | (0.45) X | ||||
| Target Price | 19.1 | ||||
| Number Of Employees | 45 | ||||
| Beta | 3.18 | ||||
| Market Capitalization | 674.88 M | ||||
| Total Asset | 260.72 M | ||||
| Retained Earnings | (519.4 M) | ||||
| Working Capital | 238.88 M | ||||
| Current Asset | 22.54 M | ||||
| Current Liabilities | 3.5 M | ||||
| Net Asset | 260.72 M |
About Fulcrum Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fulcrum Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulcrum Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulcrum Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Fulcrum Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fulcrum Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fulcrum Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fulcrum Therapeutics Stock:Check out For information on how to trade Fulcrum Stock refer to our How to Trade Fulcrum Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Pharmaceuticals sector continue expanding? Could Fulcrum diversify its offerings? Factors like these will boost the valuation of Fulcrum Therapeutics. Market participants price Fulcrum higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fulcrum Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Fulcrum Therapeutics is measured differently than its book value, which is the value of Fulcrum that is recorded on the company's balance sheet. Investors also form their own opinion of Fulcrum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fulcrum Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fulcrum Therapeutics' market value can be influenced by many factors that don't directly affect Fulcrum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fulcrum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fulcrum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fulcrum Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.